08:54 AM EDT, 09/29/2025 (MT Newswires) -- Humacyte ( HUMA ) said Monday that the US Trade and Patent Office has granted it a patent covering the composition of an investigational bioengineered esophagus made using its regenerative tissue engineering platform.

The biotech firm said the patent, which expires in 2041, protects the key structural and mechanical attributes of the bioengineered esophagus, including size, strength, and methods of production.

Shares of Humacyte ( HUMA ) were up more than 1% in recent premarket activity Monday.